Interleukin-7 immunotherapy

Claude Sportes, Ronald E. Gress

Research output: Chapter in Book/Report/Conference proceedingConference contribution

21 Citations (Scopus)

Abstract

IL-7 is a member of the common γ -chain family of cytokines sharing a common γ -chain in their receptor. Beyond its long-established pivotal role in immune development, it has been more recently recognized as a critically important regulator of peripheral naïve and memory T cell homeostasis while its role in postdevelopment thymic function remains at best, poorly defined, and controversial. Its multiple immune-enhancing properties, most notably in the maintenance of T cell homeostasis, make it a very attractive candidate for immunotherapy in a wide variety of clinical situations. Following many years of rich preclinical data in murine and simian models, IL-7 is now emerging in human phase I trials as a very promising immunotherapeutic agent. Human in vivo data discussed here are derived from the phase I study initiated at the National Cancer Institute in collaboration with Cytheris, Inc., in a cohort of subjects with incurable malignancy.

Original languageEnglish (US)
Title of host publicationImmune-Mediated Diseases
Subtitle of host publicationFrom Theory to Therapy
EditorsMichael Shurin, Yuri Smolkin
Pages321-333
Number of pages13
DOIs
StatePublished - Dec 1 2007
Externally publishedYes

Publication series

NameAdvances in Experimental Medicine and Biology
Volume601
ISSN (Print)0065-2598

Fingerprint

Interleukin-7
T-cells
Immunotherapy
Homeostasis
T-Lymphocytes
Computer peripheral equipment
National Cancer Institute (U.S.)
Maintenance
Cytokines
Data storage equipment
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Sportes, C., & Gress, R. E. (2007). Interleukin-7 immunotherapy. In M. Shurin, & Y. Smolkin (Eds.), Immune-Mediated Diseases: From Theory to Therapy (pp. 321-333). (Advances in Experimental Medicine and Biology; Vol. 601). https://doi.org/10.1007/978-0-387-72005-0_35

Interleukin-7 immunotherapy. / Sportes, Claude; Gress, Ronald E.

Immune-Mediated Diseases: From Theory to Therapy. ed. / Michael Shurin; Yuri Smolkin. 2007. p. 321-333 (Advances in Experimental Medicine and Biology; Vol. 601).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Sportes, C & Gress, RE 2007, Interleukin-7 immunotherapy. in M Shurin & Y Smolkin (eds), Immune-Mediated Diseases: From Theory to Therapy. Advances in Experimental Medicine and Biology, vol. 601, pp. 321-333. https://doi.org/10.1007/978-0-387-72005-0_35
Sportes C, Gress RE. Interleukin-7 immunotherapy. In Shurin M, Smolkin Y, editors, Immune-Mediated Diseases: From Theory to Therapy. 2007. p. 321-333. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-0-387-72005-0_35
Sportes, Claude ; Gress, Ronald E. / Interleukin-7 immunotherapy. Immune-Mediated Diseases: From Theory to Therapy. editor / Michael Shurin ; Yuri Smolkin. 2007. pp. 321-333 (Advances in Experimental Medicine and Biology).
@inproceedings{f01686b2850e423a931acb232fe36fa6,
title = "Interleukin-7 immunotherapy",
abstract = "IL-7 is a member of the common γ -chain family of cytokines sharing a common γ -chain in their receptor. Beyond its long-established pivotal role in immune development, it has been more recently recognized as a critically important regulator of peripheral na{\"i}ve and memory T cell homeostasis while its role in postdevelopment thymic function remains at best, poorly defined, and controversial. Its multiple immune-enhancing properties, most notably in the maintenance of T cell homeostasis, make it a very attractive candidate for immunotherapy in a wide variety of clinical situations. Following many years of rich preclinical data in murine and simian models, IL-7 is now emerging in human phase I trials as a very promising immunotherapeutic agent. Human in vivo data discussed here are derived from the phase I study initiated at the National Cancer Institute in collaboration with Cytheris, Inc., in a cohort of subjects with incurable malignancy.",
author = "Claude Sportes and Gress, {Ronald E.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1007/978-0-387-72005-0_35",
language = "English (US)",
isbn = "9780387720043",
series = "Advances in Experimental Medicine and Biology",
pages = "321--333",
editor = "Michael Shurin and Yuri Smolkin",
booktitle = "Immune-Mediated Diseases",

}

TY - GEN

T1 - Interleukin-7 immunotherapy

AU - Sportes, Claude

AU - Gress, Ronald E.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - IL-7 is a member of the common γ -chain family of cytokines sharing a common γ -chain in their receptor. Beyond its long-established pivotal role in immune development, it has been more recently recognized as a critically important regulator of peripheral naïve and memory T cell homeostasis while its role in postdevelopment thymic function remains at best, poorly defined, and controversial. Its multiple immune-enhancing properties, most notably in the maintenance of T cell homeostasis, make it a very attractive candidate for immunotherapy in a wide variety of clinical situations. Following many years of rich preclinical data in murine and simian models, IL-7 is now emerging in human phase I trials as a very promising immunotherapeutic agent. Human in vivo data discussed here are derived from the phase I study initiated at the National Cancer Institute in collaboration with Cytheris, Inc., in a cohort of subjects with incurable malignancy.

AB - IL-7 is a member of the common γ -chain family of cytokines sharing a common γ -chain in their receptor. Beyond its long-established pivotal role in immune development, it has been more recently recognized as a critically important regulator of peripheral naïve and memory T cell homeostasis while its role in postdevelopment thymic function remains at best, poorly defined, and controversial. Its multiple immune-enhancing properties, most notably in the maintenance of T cell homeostasis, make it a very attractive candidate for immunotherapy in a wide variety of clinical situations. Following many years of rich preclinical data in murine and simian models, IL-7 is now emerging in human phase I trials as a very promising immunotherapeutic agent. Human in vivo data discussed here are derived from the phase I study initiated at the National Cancer Institute in collaboration with Cytheris, Inc., in a cohort of subjects with incurable malignancy.

UR - http://www.scopus.com/inward/record.url?scp=34848875495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848875495&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-72005-0_35

DO - 10.1007/978-0-387-72005-0_35

M3 - Conference contribution

C2 - 17713021

AN - SCOPUS:34848875495

SN - 9780387720043

T3 - Advances in Experimental Medicine and Biology

SP - 321

EP - 333

BT - Immune-Mediated Diseases

A2 - Shurin, Michael

A2 - Smolkin, Yuri

ER -